AUS
NZ
UK
CA
USA
IND
Highlights
- Radiopharm has appointed Bruce Goodwin as Non-Executive Director, effective 19 November 2025.
- Goodwin brings over four decades of global life sciences and healthcare experience.
- He currently serves as a Non-Executive Director across six healthcare organisations, offering strategic and governance expertise.
- Phillip Hains and Dr Leila Alland to retire from the Board at the 2025 AGM.
Radiopharm Theranostics (ASX:RAD), a clinical-stage radiotherapeutics company, has announced the appointment of Mr Bruce Goodwin as a Non-Executive Director, effective 19 November 2025. The company described Mr Goodwin as a highly respected leader in the life sciences sector, with more than forty years of experience across global healthcare and biopharmaceutical industries.
Mr Goodwin currently serves as a Non-Executive Director across six healthcare organisations, providing strategic and governance oversight. His career includes over thirty years with the Janssen Pharmaceutical Companies of Johnson & Johnson, where he held senior leadership positions across multiple regions and contributed to organisational growth and innovation.
Industry Leadership and Sector Contributions
Throughout his career, Mr Goodwin has been involved in industry peak body boards in Australia and Japan, participating in policy development, regulatory discussions, and cross-sector collaboration. He is recognised for his strategic perspective and commitment to advancing health outcomes through effective governance and leadership.
Board Changes at the 2025 AGM
Radiopharm also advised that Mr Phillip Hains and Dr Leila Alland will retire from the Board at the company’s 2025 Annual General Meeting. Mr Hains will continue in his positions as Chief Financial Officer and Company Secretary following his departure from the Board.
Reflecting on the Board changes, Radiopharm’s Executive Chairman, Paul Hopper, said: “We are delighted to welcome Bruce to the Radiopharm Board. His exceptional leadership experience, particularly his long tenure with Johnson & Johnson and deep understanding of the biopharmaceutical landscape, will be invaluable as we continue to advance our pipeline and strengthen our global profile. On behalf of the Board, I would also like to thank Phillip and Leila for their contributions to Radiopharm’s growth and governance since listing. We look forward to continuing to work closely with Phillip in his executive capacities and with Leila as a consultant to the Medical Team of Radiopharm.”
Shares of RAD closed at AUD 0.022 on 19 November 2025.
